Another important mechanism of SGLT-2 inhibitor action is the aforementioned effect of canagliflozin, on the β-catenin signalling pathway in HCC cells, which represents a potential therapeutic target (Figure 1). This evidence concerns the gene SLC5A2 and hepatocellular carcinoma.